What Eikon Therapeutics, Inc. told the SEC could break it.

Exposed to potential tariffs on imported APIs and Chinese retaliatory trade measures; reinforced by key licensed assets tied to China (EIK1001 from a China-operating Cayman entity; PARP1 inhibitors licensed from Impact, a Chinese entity).

“Additionally, it is possible that further tariffs may be imposed that could affect imports of active pharmaceutical ingredients used in our product candidates, or our business may be adversely impacted by retaliatory trade measures taken by China or other countries, including restricted access to such raw materials used in our product candidates.”

Relies on third-party manufacturers and suppliers to supply its product candidates; loss of, or non-compliance/under-supply by, these parties would materially harm the business.

“We rely on third-party manufacturers and suppliers to supply our product candidates. The loss of our third-party manufacturers or suppliers, or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, within acceptable timeframes, or at all, would materially and adversely affect our business, financial condition, results of operations, and prospects.”